Christopher Yea - 21 Nov 2022 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role: Chief Development Officer
Signature: /s/ Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol: KALV
Transactions as of: 21 Nov 2022
Net transactions value: -$6,196
Form type: 4
Filing time: 21 Nov 2022, 15:21:34 UTC
Previous filing: 19 Aug 2022
Next filing: 19 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KALV	Common Stock	Options Exercise		+1,774	+5.3%		35,371	17 Nov 2022	Direct	F1
transaction	KALV	Common Stock	Sale	$6,196	-1,139	-3.2%	$5.44	34,232	18 Nov 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KALV	Restricted Stock Unit	Options Exercise	$0	-1,774	-6.7%	$0.000000	24,833	17 Nov 2022	Common Stock	1,774		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2	The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3	1/16th of the total restricted stock units subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, subject to continued service through each vesting date.